Multi-Source Brand Medication Coverage Policy
Customize your policy alerts
Sign up for all CareSource Georgia policy alerts
Know when CareSource Georgia releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior-authorization criteria and coverage conditions for approving multi-source brand (brand-with-generic-equivalents) prescription medications for CareSource Georgia members; affects providers submitting PA requests and pharmacy benefit adjudication.
No material clinical or coverage changes in this revision.
Multi-Source Brand Coverage Criteria
Multi-Source Brand Authorization Criteria
CareSource will approve use of multi-source brand medications when the following PRIOR AUTHORIZATION criteria and documentation requirements are met:
ANY of the following
- Member has a documented allergic reaction to an inactive ingredient in the generic product, with prescriber documentation of the inactive ingredient, reaction details (dates and clinical details), and the manufacturer of the generic product.
Initial Therapy Requirements
INITIAL THERAPY CRITERIA
Requirements that must be met before initial approval of a multi-source brand product when generic alternatives are available:
ANY of the following
- Trial and failure of two generic manufacturers of the requested brand-name medication at adequate dose and duration, with documentation of the unmet treatment target/goal (provide start date and duration).
- Trial and failure of all generic alternatives within the same drug class that have FDA‑approved indications for the member's condition (document trials and outcomes).
- Documented serious adverse event(s) to the generic version(s) with prescriber‑provided copy and confirmation of MedWatch form submission to the FDA (document life‑threatening event, hospitalization, disability/permanent damage, or intervention to prevent permanent impairment/damage).
- Documented allergic reaction to an inactive ingredient in the generic product with prescriber documentation of the inactive ingredient, reaction dates and clinical details, and the manufacturer of the generic product.
Continuation / Renewal Criteria
CONTINUATION CRITERIA
Criteria for renewal of ongoing coverage of an approved multi-source brand product:
ALL of the following
- Initial criteria were previously met.
- Positive clinical response to therapy with the requested brand-name product.
- No toxicities or serious adverse reactions have been experienced with the brand-name product.
Coding and Generic Trial Details
| No codes listed |
Provider Requirements & Documentation
Prior authorization and required documentation for multi-source brand requests
Prior authorization is required for each multi-source brand request. Submit the prior authorization request with chart notes and documentation including the start date and duration of prior medication trials, documentation of the treatment target or goal that was not met, paid claims evidence if the trial occurred while the member was enrolled with CareSource, and portions of the medical record confirming the diagnosis (e.g., test reports, chart notes, or hospital admission notes).
- Start date and duration of the trial must be provided
- Provide documentation of treatment target/goal that was inadequately met
- Include paid claims if the trial occurred while the member was enrolled
- Supply portions of the medical record confirming diagnoses (test reports, chart notes, hospital admission notes)
Provide MedWatch form for serious adverse events to generics
When requesting brand product due to a serious adverse event to a generic, the prescriber must provide a copy and confirmation of a MedWatch form submission to the FDA documenting the adverse outcome experienced by the member (e.g., life‑threatening event, hospitalization, disability/permanent damage, or intervention to prevent permanent impairment).
- MedWatch form must document one of: life‑threatening; required hospitalization; caused disability or permanent damage; required intervention to prevent permanent impairment/damage
- Include the copy and confirmation of submitted MedWatch form with the PA request
Key Definitions
Step Therapy and Generic Trial Table
| Step | Requirement | Exceptions |
|---|---|---|
| 1 | Member must have tried and failed two generic manufacturers of the requested brand at an adequate dose and adequate duration with documentation of the treatment target or goal that was not met. | Not applicable to exception row; see Exceptions column for allowed waivers. |
| 2 | Member must have tried and failed all generic alternatives within the same drug class that have an FDA‑approved indication for the member's condition. | Not applicable to exception row; see Exceptions column for allowed waivers. |
| 3 | If the member experienced a serious adverse event with the generic version(s), prescriber must provide a copy and confirmation of a MedWatch form submission to the FDA documenting the adverse outcome. | Serious adverse events documented via MedWatch may exempt the requirement to trial two generics (life‑threatening event, hospitalization, disability, or other qualifying outcome as documented on MedWatch). |
| 4 | If the member has a documented allergic reaction to an inactive ingredient in the generic product, prescriber documentation of the ingredient, reaction details, and manufacturer must be provided. | Documented inactive‑ingredient allergy may exempt the requirement to trial two generics. |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.